TrialTranslational psychiatry2023

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.

Megan J Shram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.